Search

The article offers information about the effects of diuretic deprescribing in heart failure patients, comparing it to ongoing diuretic use. Topics discussed include the impact on mortality and heart failure recurrence, the variability in cardiovascular outcomes, and the tolerability of diuretic discontinuation.

A recent study investigated the potential of low-dose colchicine treatment in reducing cardiovascular disease risk in hypertensive rats. The study found that daily oral administration of low-dose colchicine prevented increases in mean arterial pressure and improved vasorelaxation in the rats. Colchicine treatment also attenuated arterial remodeling, reduced inflammation, and decreased left ventricular hypertrophy. These findings suggest that colchicine has the potential to elicit cardiovascular protective effects in hypertension by targeting multiple cell types. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

A recent study conducted by researchers at the University of Georgia has found that probenecid, a host-targeting antiviral drug, has the potential to inhibit the replication of Human Metapneumovirus (HMPV). HMPV is a common cause of acute respiratory tract infections and can lead to significant morbidity and mortality. The study showed that probenecid was effective in inhibiting HMPV replication both in vitro and in mice. These findings suggest that probenecid could be a potential treatment option for HMPV infections, as currently there are no specific antiviral drugs or vaccines available. [Extracted from the article]

Researchers from Tianjin University in China have conducted a study on antigout agents, specifically focusing on the drug probenecid (PRO) and its low solubility. They synthesized and characterized two salts of PRO, 4-aminopyridine (4AMP) and 4-dimethylaminopyridine (4DAP), and found that the solubility of PRO salts increased significantly compared to the raw drug. The salts also demonstrated good phase stability over 8 weeks. The study analyzed the intermolecular interactions and calculated lattice energy and hydration-free energy to understand the relationship between these parameters and the changes in solubility. This research provides valuable insights into the development of more effective antigout agents. [Extracted from the article]

A recent study conducted at the University of North Carolina has found that the use of allopurinol can help manage skewed 6-mercaptopurine (6MP) metabolism in pediatric maintenance acute lymphoblastic leukemia (ALL) treatment. 6MP is commonly used in maintenance therapy for pediatric ALL, but it is associated with adverse drug effects. The study found that allopurinol significantly increased the time spent in the therapeutic absolute neutrophil count (ANC) range and lowered the ratio of 6MP metabolites, reducing the side effects of 6MP and optimizing its anti-leukemic effects. This research provides valuable insights for improving the treatment of pediatric ALL. [Extracted from the article]

A recent study conducted at the University Medical Centre Hamburg-Eppendorf (UKE) in Germany explored the optimization of thiopurine therapy in autoimmune hepatitis (AIH). The researchers investigated whether patients could be stratified based on their response to thiopurine metabolites and examined the effects of azathioprine dosage increases and co-therapy with allopurinol on metabolite profiles and treatment response. The study found that maintaining complete biochemical remission (CBR) in AIH was associated with specific levels of thiopurine metabolites. For patients who did not achieve CBR despite dose increases, the addition of allopurinol alongside low-dose thiopurines was found to be an effective alternative. [Extracted from the article]

Researchers from Qom University of Medical Sciences conducted a randomized controlled trial to study the efficacy of low-dose colchicine on the clinical outcomes of patients with ST-elevation myocardial infarction (STEMI). The study included 172 STEMI patients and found that the addition of colchicine did not significantly improve patient outcomes after a 40-day follow-up period. The researchers concluded that there was no significant benefit in enhancing the outcomes of patients with STEMI through the use of colchicine. The study was registered on the Iranian registry of clinical trials. [Extracted from the article]

A recent study conducted by researchers at the University of Nebraska Medical Center focused on antigout agents and their potential use in treating lymphatic filariasis (LF), a debilitating disease caused by parasitic infections. The researchers developed a method using LC-MS/MS technology to accurately measure the levels of albendazole and its metabolites, as well as probenecid, in human plasma and dried blood spots. The study found that this method was effective in identifying these compounds at low concentrations, even with small specimen volumes obtained from dried blood spots. This research has important implications for therapeutic drug monitoring in remote locations for LF patients. [Extracted from the article]

A systematic review conducted by researchers at Centre hospitalier de Versailles in France explored the potential use of tocilizumab (TCZ) in the treatment of familial Mediterranean fever (FMF). FMF is an autoinflammatory disease characterized by recurrent fever and serosal inflammation. While colchicine is the primary treatment, approximately 10% of FMF patients do not respond to it, necessitating alternative therapies. The review found that TCZ may be beneficial for FMF patients with established renal AA amyloidosis and resistance to colchicine and interleukin 1 inhibitors. However, more research is needed to fully understand the safety and efficacy of TCZ in FMF. [Extracted from the article]

A recent study conducted by researchers at the University of Montreal aimed to identify genetic determinants of allopurinol metabolism and concentrations in patients undergoing allopurinol therapy. The study involved 439 participants and investigated four endpoints, including plasma concentrations of oxypurinol (the active metabolite of allopurinol), allopurinol, allopurinol-riboside, and allopurinol daily dosing. However, no associations reached the predefined genome-wide threshold values for any of the endpoints. The researchers concluded that collaborative investigations involving larger and diverse cohorts may be necessary to further identify pharmacogenomic determinants of allopurinol and personalize allopurinol therapy. [Extracted from the article]

A study conducted in Japan explored the association between urate-lowering agents and reduced response to erythropoietin-stimulating agents in patients with advanced chronic kidney disease. The study categorized patients into four groups based on their use of urate-lowering drugs: high-dose allopurinol, low-dose allopurinol, febuxostat, and no-treatment groups. The results showed a statistically significant association between the high-dose allopurinol group and erythropoietin hyporesponsiveness. The study suggests that the use of high-dose allopurinol exceeding the optimal dose may lead to hyporesponsiveness to erythropoiesis-stimulating agents. [Extracted from the article]

Researchers at the University of Laval in Quebec City, Canada have developed a series of novel pyridinyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates (PYRIB-SOs) that have shown antiproliferative activity against breast cancer cell lines. These compounds were found to act as antimitotics, binding to the colchicine-binding site of alpha, beta-tubulin and disrupting the cell cycle progression. The researchers believe that these PYRIB-SOs have potential as promising antimitotics and should be further studied for their biopharmaceutical and pharmacodynamic properties. This research was funded by various organizations and has been peer-reviewed. [Extracted from the article]

A study conducted by the University of Tampere in Finland examined the association between allopurinol use and prostate cancer survival. Allopurinol is a medication used to treat gout by inhibiting uric acid formation. Previous studies suggested that long-term use of allopurinol may reduce the incidence of prostate cancer, but the Finnish study did not support these findings. The study analyzed data from a Finnish population-based cohort of 9,252 men diagnosed with prostate cancer between 1996 and 2015. The results showed that there was no difference in prostate cancer-specific survival (CSS) between allopurinol users and non-users, but allopurinol users had lower overall survival (OS). However, the decrease in OS was mitigated with increasing intensity of allopurinol use. The researchers concluded that allopurinol use may not have anticancer effects against prostate cancer, but instead may be a surrogate for metabolic problems causing shorter overall survival among men with prostate cancer. [Extracted from the article]

Researchers at the Sardar Vallabhbhai National Institute of Technology in Surat, India, have conducted a study on the impact of various process parameters on the particle size of Febuxostat (FEB) nanocrystals. They used the continuous microchannel nanoprecipitation technique with poloxamer 407 as the polymer to produce the nanoparticles. The study found that microchannel length, drug concentration, and polymer-to-drug ratio significantly influenced the particle size of the nanocrystals. The researchers concluded that the microfluidic nanoprecipitation technique has great potential for reducing the size of drug crystals to the nanoscale. [Extracted from the article]

A recent report from the University Medical Center Utrecht discusses the findings of a study on atherosclerosis, a condition characterized by the buildup of plaque in the arteries. The study identified five major subtypes of atherosclerotic plaques and examined the differential expression of drug-responsive genes in these subtypes. The researchers found that there were significant differences in gene expression levels between the plaque subtypes, suggesting that different drugs used to treat atherosclerosis may have varying effects depending on the subtype of plaque. This research provides valuable insights into personalized treatment approaches for atherosclerosis. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the potential of a new compound, 60c, in treating metastatic, triple-negative breast cancer (TNBC). TNBC is a challenging subtype of breast cancer that lacks targetable receptors. Current therapies for TNBC include cytotoxic chemotherapies, but there are no FDA-approved drugs that bind to the colchicine-binding site. The study found that 60c showed improved potency compared to an existing inhibitor, VERU-111, in both taxane-sensitive and taxane-resistant TNBC models. It also demonstrated unique anti-metastatic effects, suppressing metastases in various organs. This research is still in the preprint stage and has not undergone peer review. [Extracted from the article]

A recent report from the Icahn School of Medicine at Mount Sinai discusses the role of colchicine, an antigout agent, in cardiovascular disorders. The report highlights the importance of anti-inflammatory therapies in improving cardiovascular outcomes, as inflammation plays a significant role in conditions like atherosclerosis. Colchicine has shown promise as a novel anti-inflammatory agent in cardiovascular diseases, with landmark trials supporting its efficacy and safety in reducing major adverse cardiovascular events. However, careful monitoring for drug interactions and adverse effects is necessary. The report provides a comprehensive summary of colchicine's mechanisms of action, targets in various cardiovascular conditions, pharmacokinetics, and evidence on its safety and efficacy in treating cardiovascular disorders. [Extracted from the article]

A study conducted at Huazhong University of Science and Technology in Hubei, China, investigated the effects of allopurinol on coronary plaque stabilization in patients with acute coronary syndrome (ACS). Allopurinol is a medication that reduces inflammation and oxidative stress in patients with cardiovascular disease. The study found that allopurinol did not significantly improve plaque stability or inflammation in ACS patients. These findings suggest that allopurinol may not be effective in modifying coronary plaque in ACS. [Extracted from the article]

A recent study conducted in Ankara, Turkey, focused on familial Mediterranean fever (FMF), a condition characterized by febrile polyserositis attacks. The researchers specifically examined adolescent FMF patients with menstruation-associated attacks and proposed a management algorithm. The study found that patients with menstruation-associated FMF attacks had different characteristics compared to those without such attacks, including a higher rate of dysmenorrhea and higher attack frequency. The interventions for menstruation-associated attacks included various treatments such as colchicine, anti-inflammatory drugs, and glucocorticoids. The study concluded that on-demand therapies could be beneficial in managing these attacks. [Extracted from the article]

A recent report from researchers at Zhengzhou University discusses the potential use of low-dose colchicine as a treatment for doxorubicin-induced cardiotoxicity. Doxorubicin is a commonly used chemotherapy drug that can cause damage to the heart. The researchers found that low-dose colchicine improved heart function and promoted the degradation of autolysosomes, which mitigated the cardiotoxic effects of doxorubicin. This study suggests that colchicine may be a promising therapeutic option for reducing the cardiotoxicity associated with doxorubicin treatment. [Extracted from the article]

A study conducted at Prince Sattam Bin Abdulaziz University has developed a new method for simultaneously analyzing the antihyperuricemic agents lesinurad (LND) and febuxostat (FBX) in commercially available fixed-dose combination tablets. The method utilizes a greener normal-phase high-performance thin-layer chromatography (HPTLC) technique, which is fast, sensitive, and environmentally friendly. The study confirmed that the method is accurate, precise, robust, and green, and the LND and FBX contents in the tablet products were found to be within the acceptable range. This research provides a valuable approach for determining the levels of LND and FBX in pharmaceutical combination products. [Extracted from the article]

A patent has been issued for a composition and method for treating refractory painful intervertebral disc related disorders. The composition includes magnesium chloride and colchicine, which have vasodilating, antispasmodic, anti-inflammatory, and antioxidant properties. The treatment involves administering the composition via an intravenous drip over a course of 13-15 weeks. This non-invasive treatment option aims to reduce chronic spinal pain and is intended for patients who have not responded to other therapies. [Extracted from the article]

A recent study conducted by Tel Aviv University in Israel compared the effectiveness and safety of two different treatment strategies for children with colchicine-resistant familial Mediterranean fever (crFMF). The study focused on the use of canakinumab, a monoclonal antibody that targets interleukin-1 beta. The first treatment strategy involved monthly subcutaneous injections of canakinumab, while the second strategy, known as the "canakinumab on demand" (COD) policy, allowed for wider intervals between drug administrations. The study found that both treatment strategies resulted in a significant reduction in FMF attacks, with similar efficacy and safety. However, the COD policy required a lower accumulated dose of canakinumab, making it less immunosuppressive and less expensive. [Extracted from the article]

Researchers from Aristotle University of Thessaloniki in Greece have developed a sensitive and selective gas chromatography-electron capture detector (GC-ECD) method for quantifying trace levels of genotoxic impurities in the antihyperuricemic agent Febuxostat. The method was validated according to ICH guidelines and achieved accurate and precise results. The researchers successfully applied the method to determine impurities in various Febuxostat samples. This research provides valuable insights for the pharmaceutical industry in ensuring the safety and quality of antihyperuricemic agents. [Extracted from the article]

A recent case report from New York University NYU Langone Health discusses the cardiotoxic effects of sodium azide, a substance that inhibits complex IV in the electron transport chain, blocking ATP synthesis. Sodium azide exposure is rare but can be lethal, and there is currently no known antidote. The case report describes a 31-year-old patient with major depressive disorder who experienced altered mental status after ingesting an unknown amount of sodium azide. The patient developed pleuritic chest pain and was diagnosed with sodium azide-induced myopericarditis. Treatment with colchicine resulted in complete symptom resolution. This is the first reported case of sodium azide-induced myopericarditis with a preserved left ventricular ejection fraction treated with colchicine. [Extracted from the article]

A recent report discusses research on pericarditis conducted by researchers at the Cleveland Clinic. The study aimed to determine if the addition of colchicine to anakinra treatment could prevent recurrences of pericarditis more effectively than anakinra alone. The study included 256 patients, and after a 12-month follow-up, it was found that patients treated with both anakinra and colchicine had a lower incidence of recurrences and longer event-free survival compared to those treated with anakinra alone. The researchers concluded that the addition of colchicine to anakinra treatment could be helpful in reducing recurrences and prolonging recurrence-free survival. [Extracted from the article]

A new report from researchers at Imperial College London provides fresh data on antigout agents. The study focuses on multidrug resistance-associated protein 2 (MRP2/ABCC2), which is an efflux transporter of organic anions expressed in hepatocyte canalicular membranes. The researchers determined the cryo-EM structure of rat Mrp2 (rMrp2) in an autoinhibited state and in complex with the uricosuric drug probenecid. They found that phosphorylation of the regulatory domain relieves autoinhibition and enhances transport activity. The study also suggests that Dubin-Johnson mutations may interfere with the transition between conformational states. [Extracted from the article]

A study conducted at Saga University in Japan investigated the effect of the xanthine oxidase inhibitor, febuxostat, on white blood cell (WBC) count in patients with asymptomatic hyperuricemia. The study found that febuxostat therapy for 24 months modestly reduced WBC count in these patients, suggesting a potential anti-inflammatory action of febuxostat in clinical settings. The research was a post hoc subanalysis of a larger clinical trial and was supported by Teijin Pharma Limited, Japan. The findings contribute to the understanding of the effects of urate-lowering therapy on inflammation and cardiovascular health. [Extracted from the article]

A recent report from the Beijing Institute of Pharmacology and Toxicology discusses the delivery strategies for colchicine, a widely used natural drug for treating gout. The report highlights that while colchicine has potent anti-inflammatory effects, its clinical application is limited due to serious gastrointestinal adverse effects. The researchers explore different delivery strategies, including transdermal, injection, and oral routes, and emphasize the potential benefits of transdermal drug delivery in reducing toxicity and enhancing efficacy. The report also briefly discusses permeation-promoting technologies for transdermal drug delivery systems. This research provides scientific ideas and theoretical guidance for future studies on colchicine delivery strategies. [Extracted from the article]

A recent study conducted by researchers at Sichuan University in Chengdu, China, has explored the potential mechanism of colchicine-induced liver damage. Colchicine is commonly used to treat gouty arthritis, familial Mediterranean fever, cardiovascular dysfunction, and new coronary pneumonia. However, excessive intake of colchicine can lead to lethal liver damage. The researchers found that the enzyme CYP1A1 plays a significant role in colchicine-induced hepatotoxicity and its metabolism. Inhibiting CYP1A1 can alleviate oxidative stress and pyroptosis in the liver, effectively reducing colchicine-induced liver injury. This study suggests that CYP1A1 may be a potential target for mitigating the hepatotoxic effects of colchicine. [Extracted from the article]

A report from Adam Mickiewicz University in Poznan, Poland discusses research on anticancer agents using machine learning. The study aimed to assess the anticancer potential of colchicine-based compounds and develop machine learning models to predict anticancer activity. The researchers used various algorithms to create predictive models and established a library of new colchicine-based compounds. The study concluded that the most proficient model was able to reasonably estimate anticancer activity based on molecular structure input. This research provides valuable insights into the application of machine learning in medicinal chemistry and the development of new anticancer drugs. [Extracted from the article]

A recent meta-analysis conducted by researchers at the University of South China compared the efficacy of two common drugs, febuxostat and benzbromarone, in the treatment of gout. The study analyzed 7 studies that met the inclusion criteria and found that febuxostat had a better uric acid-reducing effect and improved renal function-related indexes compared to benzbromarone. However, benzbromarone was found to have less hepatotoxicity. The researchers concluded that further research is needed to confirm the specific efficacy of these drugs. [Extracted from the article]

A recent report from researchers at Sichuan University in Chengdu, China, explores the hepatotoxicity (liver damage) caused by colchicine, a drug commonly used to treat gouty arthritis. The study used metabolomic analysis to identify 17 metabolites of colchicine, including 3 novel sulfated metabolites. The researchers found that colchicine may regulate sulfotransferase 1 (SULT1) through perixisome proliferation-activated receptor alpha (PPAR alpha), and inhibition of SULT1 worsened colchicine-induced liver injury. However, supplementation of endogenous sulfated metabolites alleviated liver injury. The study suggests that targeting the SULT1 enzyme and administering specific metabolites may be useful in mitigating colchicine hepatotoxicity. [Extracted from the article]

A recent study conducted by researchers at the University of Otago in New Zealand has highlighted the importance of colchicine in managing various conditions, including gout and familial Mediterranean fever. However, the study also emphasizes the potential risks associated with colchicine due to its narrow therapeutic index, which has been linked to overdose and fatalities. The researchers suggest that strategies to minimize the risk of colchicine poisoning should focus on unauthorized access, intentional overdose, and inappropriate dosing. Culturally sensitive education about the proper storage and use of colchicine is crucial in order to prevent overdose. [Extracted from the article]

Researchers at Washington State University have conducted a study on the effects of probenecid on the blood levels and renal elimination of furosemide and endogenous compounds in rats. The study aimed to identify potential biomarkers for transporter-mediated drug-drug interactions (DDIs) during early phases of clinical trials. The researchers found that pyridoxic acid and kynurenic acid, previously considered as potential biomarkers, had limited utility for predicting DDIs in rats. However, they identified 21 putative biomarkers belonging to various metabolic pathways that could be used to predict DDIs caused by organic anion transporters (OATs) in rats. [Extracted from the article]

A recent study conducted by researchers at the University of Health Sciences in Istanbul, Turkey, focused on the successful management of a colchicine overdose using plasmapheresis therapy. Colchicine is a medication used to treat gout, but an overdose can be lethal due to its narrow therapeutic index. The study describes the case of a 32-year-old female who intentionally ingested a large amount of colchicine and was treated with plasmapheresis and supportive therapy. The patient experienced only one-day transient lymphopenia during the four days of observation. This research provides valuable insights into the management of colchicine overdose. [Extracted from the article]

Researchers at Nanjing University in China have discovered a series of novel compounds, called Spartinin C1-C24, that have the potential to lower serum uric acid levels. These compounds were derived from components found in the coastal marine source Spartina alterniflora and marketed drugs. The top hits, Spartinin C10 and C22, showed high inhibition percentages against xanthine oxidase, a key enzyme involved in uric acid production. Spartinin C10 was found to be comparable to the positive control drug Allopurinol in lowering serum uric acid levels in hyperuricemic model mice. The researchers believe that this discovery of pharmaceutical molecules from a coastal marine source could inspire further investigations in public health. [Extracted from the article]

Researchers at Universite de Tunis El Manar have published a case report on pediatric colchicine poisoning. Colchicine is a tricyclic alkaloid that can be both medicinal and poisonous. The report describes the case of a 13-year-old girl who presented with symptoms such as vomiting, abdominal pain, and fever. It was later discovered that she had ingested 40 tablets of colchicine in a suicide attempt. Despite a delayed diagnosis, the girl was successfully treated with supportive measures such as corticosteroids and immunoglobulin. The researchers suggest that further research is needed to determine the effectiveness of these treatments for severe colchicine intoxication. [Extracted from the article]

Researchers from Mazandaran University of Medical Sciences in Sari, Iran, have conducted a study evaluating the antihypoxic activities of colchicine, an anti-inflammatory drug primarily used for gout treatment. The researchers found that colchicine showed good protective effects against hypoxia in circulatory and haemic models, with the drug being more effective than the positive control, propranolol. However, colchicine did not show any activity in the asphyctic model. This research suggests that colchicine may have potential benefits in protecting against hypoxia-induced lethality. [Extracted from the article]

A recent study conducted by researchers at Nanjing University in China has developed a new animal model of chronic gout that closely mimics the disease in humans. The model involves daily injections of potassium oxonate, a high-fat diet, and injections of acetic acid into the hind paws of mice. After four months, the mice in the model group showed increased arthritis severity, joint and cartilage damage, and bone erosion. The researchers believe that this model will provide valuable insights into the pathogenesis of gout and can be used to screen potential antigout agents. [Extracted from the article]

A recent study conducted by researchers at Huazhong University of Science and Technology focused on the effects of different anti-inflammatory drugs on high-sensitivity C-reactive protein (hsCRP) levels in patients after percutaneous coronary intervention (PCI). The study included 132 patients who completed the planned PCI and were treated with aggressive secondary prevention strategies for four weeks. The patients were randomly assigned to different treatment groups, including a control group and groups receiving colchicine, tranilast, or oridonin. The primary outcome measured was the percentage change in hsCRP levels after four weeks of treatment. The study found that only the colchicine group showed a significant reduction in hsCRP levels compared to the control group. Proteomic analysis also revealed that colchicine therapy reduced proteins associated with neutrophil activation, platelet aggregation, and endothelial damage. This study suggests that colchicine may be effective in reducing hsCRP levels in patients after PCI. [Extracted from the article]

Keywords: Salzburg; Austria; Europe; Antigout Agents; Antineoplastics; Colchicine Therapy; Drugs and Therapies; Health and Medicine; Microtubule Proteins; Nerve Tissue Proteins; Pharmaceuticals; Tubulin EN Salzburg Austria Europe Antigout Agents Antineoplastics Colchicine Therapy Drugs and Therapies Health and Medicine Microtubule Proteins Nerve Tissue Proteins Pharmaceuticals Tubulin 1032 1032 1 11/06/23 20231110 NES 231110 2023 NOV 10 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Drugs and Therapies - Antigout Agents. Salzburg, Austria, Europe, Antigout Agents, Antineoplastics, Colchicine Therapy, Drugs and Therapies, Health and Medicine, Microtubule Proteins, Nerve Tissue Proteins, Pharmaceuticals, Tubulin. [Extracted from the article]

Allopurinol Therapy, Antihyperuricemic Agents, Drugs and Therapies, Health and Medicine, Hematologic Diseases and Conditions, Pharmaceuticals, Von Willebrand Disease, Antigout Agents Keywords: Allopurinol Therapy; Antigout Agents; Antihyperuricemic Agents; Drugs and Therapies; Health and Medicine; Hematologic Diseases and Conditions; Pharmaceuticals; Von Willebrand Disease EN Allopurinol Therapy Antigout Agents Antihyperuricemic Agents Drugs and Therapies Health and Medicine Hematologic Diseases and Conditions Pharmaceuticals Von Willebrand Disease 2980 2980 1 11/06/23 20231110 NES 231110 2023 NOV 10 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on von Willebrand disease. [Extracted from the article]

Antigout Agents, Antihyperuricemic Agents, Arthritis, Drugs and Therapies, Febuxostat, Febuxostat Therapy, Gout, Gouty Arthritis, Health and Medicine, Inborn Errors Purine-Pyrimidine Metabolism, Joint Diseases and Conditions, Musculoskeletal Diseases and Conditions, Nutritional and Metabolic Diseases and Conditions, Pharmaceuticals, Rheumatic Diseases and Conditions Keywords: Antigout Agents; Antihyperuricemic Agents; Arthritis; Drugs and Therapies; Febuxostat; Febuxostat Therapy; Gout; Gouty Arthritis; Health and Medicine; Inborn Errors Purine-Pyrimidine Metabolism; Joint Diseases and Conditions; Musculoskeletal Diseases and Conditions; Nutritional and Metabolic Diseases and Conditions; Pharmaceuticals; Rheumatic Diseases and Conditions EN Antigout Agents Antihyperuricemic Agents Arthritis Drugs and Therapies Febuxostat Febuxostat Therapy Gout Gouty Arthritis Health and Medicine Inborn Errors Purine-Pyrimidine Metabolism Joint Diseases and Conditions Musculoskeletal Diseases and Conditions Nutritional and Metabolic Diseases and Conditions Pharmaceuticals Rheumatic Diseases and Conditions 476 476 1 11/06/23 20231106 NES 231106 2023 NOV 9 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Current study results on gout have been published. [Extracted from the article]

According to the news editors, the research concluded: "Altogether, colchicine, a bioactive constituent from an ancient medicinal herb, exerts unique anti-inflammatory effects and prominent cardiovascular actions, and will charter a new page in cardiovascular medicine." Keywords: Hefei; People's Republic of China; Asia; Antigout Agents; Cardiology; Cardiovascular; Cardiovascular Research; Clinical Research; Clinical Trials and Studies; Colchicine Therapy; Drugs and Therapies; Health and Medicine; Pharmaceuticals; Pharmacology; Therapy EN Hefei People's Republic of China Asia Antigout Agents Cardiology Cardiovascular Cardiovascular Research Clinical Research Clinical Trials and Studies Colchicine Therapy Drugs and Therapies Health and Medicine Pharmaceuticals Pharmacology Therapy 1136 1136 1 10/30/23 20231031 NES 231031 2023 OCT 30 (NewsRx) -- By a News Reporter-Staff News Editor at Heart Disease Weekly -- Researchers detail new data in Drugs and Therapies - Antigout Agents. [Extracted from the article]

Keywords: Antigout Agents; Colchicine Therapy; Drugs and Therapies; Health and Medicine; Pharmaceuticals EN Antigout Agents Colchicine Therapy Drugs and Therapies Health and Medicine Pharmaceuticals 2422 2422 1 10/24/23 20231027 NES 231027 2023 OCT 27 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Data detailed on antigout agents have been presented. Antigout Agents, Colchicine Therapy, Drugs and Therapies, Health and Medicine, Pharmaceuticals Keywords for this news article include: University Hospital Fuenlabrada, Antigout Agents, Pharmaceuticals, Colchicine Therapy, Drugs and Therapies, Health and Medicine. [Extracted from the article]

For more information on this research see: A Novel Role of Uricosuric Agent Benzbromarone In Bk Channel Activation and Reduction of Airway Smooth Muscle Contraction Br. Molecular Pharmacology, 2023;103(3). Keywords: Qingdao; People's Republic of China; Asia; Antiarrhythmic Agents; Benzbromarone Therapy; Drugs and Therapies; Gout Suppressants; Health and Medicine; Pharmaceuticals; Pharmacology; Renal Agents; Therapy; Uricosuric Agents EN Qingdao People's Republic of China Asia Antiarrhythmic Agents Benzbromarone Therapy Drugs and Therapies Gout Suppressants Health and Medicine Pharmaceuticals Pharmacology Renal Agents Therapy Uricosuric Agents 784 784 1 10/09/23 20231013 NES 231013 2023 OCT 9 (NewsRx) -- By a News Reporter-Staff News Editor at Respiratory Therapeutics Week -- Investigators publish new report on Drugs and Therapies - Renal Agents. Qingdao, People's Republic of China, Asia, Antiarrhythmic Agents, Benzbromarone Therapy, Drugs and Therapies, Gout Suppressants, Health and Medicine, Pharmaceuticals, Pharmacology, Renal Agents, Therapy, Uricosuric Agents. [Extracted from the article]

Berlin, Germany, Europe, Antigout Agents, Colchicine Therapy, Drugs and Therapies, Familial Mediterranean Fever, Health and Medicine, Hereditary Autoinflammatory Diseases and Conditions, Pediatrics, Pharmaceuticals Keywords for this news article include: Antigout Agents, Pharmaceuticals, Berlin, Europe, Germany, Pediatrics, Colchicine Therapy, Drugs and Therapies, Health and Medicine, Familial Mediterranean Fever, Hereditary Autoinflammatory Diseases and Conditions. Keywords: Berlin; Germany; Europe; Antigout Agents; Colchicine Therapy; Drugs and Therapies; Familial Mediterranean Fever; Health and Medicine; Hereditary Autoinflammatory Diseases and Conditions; Pediatrics; Pharmaceuticals EN Berlin Germany Europe Antigout Agents Colchicine Therapy Drugs and Therapies Familial Mediterranean Fever Health and Medicine Hereditary Autoinflammatory Diseases and Conditions Pediatrics Pharmaceuticals 120 120 1 10/09/23 20231009 NES 231009 2023 OCT 14 (NewsRx) -- By a News Reporter-Staff News Editor at Pediatrics Week -- New research on Autoinflammatory Diseases and Conditions - Familial Mediterranean Fever is the subject of a report. [Extracted from the article]

Anti-interleukin-1 (anti-IL-1) agents are alternative treatment options for colchicine-resistant or -intolerant FMF patients. Keywords: Istanbul; Turkey; Eurasia; Adverse Drug Reactions; Antigout Agents; Colchicine Therapy; Cytokines; Drugs and Therapies; Familial Mediterranean Fever; Health and Medicine; Hereditary Autoinflammatory Diseases and Conditions; Intercellular Signaling Peptides and Proteins; Interleukin-1; Interleukins; Monokines; Pediatrics; Peptides; Pharmaceuticals; Proteins EN Istanbul Turkey Eurasia Adverse Drug Reactions Antigout Agents Colchicine Therapy Cytokines Drugs and Therapies Familial Mediterranean Fever Health and Medicine Hereditary Autoinflammatory Diseases and Conditions Intercellular Signaling Peptides and Proteins Interleukin-1 Interleukins Monokines Pediatrics Peptides Pharmaceuticals Proteins 273 273 1 10/09/23 20231009 NES 231009 2023 OCT 14 (NewsRx) -- By a News Reporter-Staff News Editor at Pediatrics Week -- New research on Autoinflammatory Diseases and Conditions - Familial Mediterranean Fever is the subject of a report. [Extracted from the article]